AllPeptides.eu - Advanced Peptide Research
    Single Peptides
    Bioregulator

    Prostamax (20mg)

    Subcutaneous injectionDaily20mg

    Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16

    🇷🇺 МЗ РФ (Простамакс®)

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Approved by select regulatory agencies — not FDA/EMA
    Educational information. Not medical advice or a recommendation for use.

    ⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer

    Free Access

    How It Works

    Prostamax epigenetically regulates gene expression in prostate cells, reducing inflammation, improving microcirculation, and supporting normal cellular renewal.

    Quick Start

    • Typical dose: 1–2mg subcutaneously
    • Frequency: Daily for 10–20 days
    • Storage: 2–8°C after reconstitution
    Detailed Protocol Data

    Dosing Table — Prostamax 20mg

    Educational only
    Vial Size— affects syringe units
    BAC Water2 mL
    Concentration10.00 mg/mL

    Route: Subcutaneous injection | Frequency: Daily

    WeekDoseUnits (per injection)
    1–2
    1mg
    10 Units (0.10 mL)
    3+
    2mg
    20 Units (0.20 mL)

    10–20 day cycle, repeated every 3–6 months.

    Related compounds

    Reconstitution Steps

    1. Clean the vial stoppers with an alcohol wipe.
    2. Draw up 2mL of bacteriostatic water.
    3. Inject slowly down the side wall of the vial.
    4. Gently swirl until fully dissolved.
    5. Store in the refrigerator (2–8°C).

    Protocol Overview

    • Prostate bioregulator — epigenetic regulation of prostate tissue genes.
    • Used in health protocols for men >40 years of age.
    • Studies show improvement in urodynamic parameters.

    Dosing Protocol

    • 1–2mg/day for 10–20 days.
    • Repeat every 3–6 months.
    • Combines with Testagen for male health.
    • Break between cycles: After the cycle (10–20 days), a 3–6 month break is recommended. Khavinson bioregulators — typically 2–3 cycles/year.

    Washout & Cycle Restart

    When can I restart?

    After the cycle (10–20 days), a 3–6 month break is recommended. Khavinson bioregulators — typically 2–3 cycles/year.

    Minimum wait period: 12 weeks

    Storage Instructions

    • Reconstituted: 2–8°C, use within 21 days.
    • Powder: 2–8°C.

    Important Notes

    • Check PSA levels before and after the cycle.
    • Contraindicated in known prostate cancer.
    • Cumulative effect — results are seen after the cycle.
    Clinical Analysis & Safety

    Potential Benefits & Side Effects

    Potential Benefits:

    • Prostate health support
    • Improvement of urological symptoms
    • Anti-inflammatory action
    • Anti-aging effect on the prostate

    Potential Side Effects:

    • Mild injection site irritation
    • Rare: transient pelvic discomfort

    ⚠️ Serious Warnings & Long-Term Risks

    The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.

    🎗️ Cancer Markers
    🟡 Moderate / Theoretical

    Prostate bioregulator — theoretical risk in prostate cancer

    Regulates prostate tissue. In patients with undiagnosed or progressing prostate cancer, trophic action on prostate cells could theoretically worsen disease.

    📄 Khavinson VK — Bull Exp Biol Med

    References

    1. Prostate Bioregulation — Khavinson VK, et al. Effect of peptide bioregulators on prostate function. Bull Exp Biol Med. 2006;141(1):89-92.
      View Source
    2. Khavinson Peptides — Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144.
      View Source

    Recommended Supplements

    Research Sources & Verified Data
    …
    Clinical Trials
    …
    PubMed Studies
    Research-only
    FDA Status
    1
    Regulatory Approvals
    Verified across ClinicalTrials.gov, PubMed & FDA

    External Sources & Regulatory Status

    Regulatory Approvals

    🇷🇺
    МЗ РФ
    Approved

    Простамакс® · Prostate (2007)

    Approved in Russia (Khavinson bioregulator)

    No official regulatory source available yet — research peptide.

    Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.

    Summary:
    1 Approvals
    0 PubMed
    0 Clinical Studies

    Continue Your Research

    Explore tools and guides related to this protocol.

    Educational contentRegularly reviewed & maintainedEvidence-based review

    Important Disclaimer

    The content of this website is provided exclusively for informational and educational purposes within the context of research literature.

    Read the full Disclaimer →

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu